AUT and PharmaCann team up to research and develop medicinal cannabis products.

Medicinal cannabis products will soon be researched and developed ready for changing government legislation.

 Auckland University of Technology (AUT) and PharmaCann New Zealand Ltd signed an agreement of collaboration on Thursday. 

“It is important to increase scientific understanding of the ways in which cannabis and cannabis derivatives can benefit health,” AUT Dean of Health and Environmental Sciences Max Abbott said.

“It is also important that these products are of known and reliable quality and are affordable,” Abbott said.

Chloe Swarbrick’s medicinal cannabis bill fails at first reading
Government marijuana bill gains support from all parties, but fate of Greens’ bill unclear
How does cannabis actually affect the human body?

The parties aim to have therapeutic formulations developed and in clinical trials by the time new government regulations for cannabis come into force.

“PharmaCann intends to develop innovative cannabis-based products for therapeutic use by New Zealand patients and to serve global markets,” says PharmaCann CEO Chris Fowlie.

“Our partnership with AUT will help accelerate product development and ensure products are rigorously assessed and made to the highest standards.”

Although New Zealand doctors can now prescribe the medical product cannabidiol (CBD), it can only be sourced from overseas and is not eligible for Pharmac funding, making it prohibitively expensive and out of reach of most New Zealanders.

“Our vision is to develop and manufacture in New Zealand natural cannabis-based products that are as good as anything available overseas, at more affordable prices for patients,” says Fowlie.

Ad Feedback

AUT’s Drug Delivery Research Group will work on extraction of medicinal compounds from locally grown plants and the development of oral and topical (skin) formulation.

 – Stuff

Read More Here...